17.06.2013 Views

EAU 2013 - Programme Book - YouMed

EAU 2013 - Programme Book - YouMed

EAU 2013 - Programme Book - YouMed

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

104 Overall survival with cabazitaxel is strongly related to PSA response: Results of a retrospective registry in<br />

metastatic castration resistant prostate cancer (mCRPC)<br />

A. Angelergues, F. Mercier, A. Flechon, A. Guillot, S. Le Moulec, G. Gravis, P. Beuzeboc, C. Massard,<br />

K. Fizazi, T. De La Motte Rouge, R. Elaidi, S. Oudard (Paris, Port-Mort, Lyon, St-Etienne, Marseille, Villejuif,<br />

France)<br />

105 Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase III study of abiraterone<br />

acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)<br />

H. Suttmann, P.F.A. Mulders, A. Molina, O.B. Goodman, Jr., T.W. Flaig, J. Li, T. Kheoh, J.S. De Bono, H.I. Scher<br />

(Hamburg, Germany; Nijmegen, The Netherlands; Los Angeles, Las Vegas, Aurora, Raritan, New York,<br />

United States of America; Sutton, United Kingdom)<br />

106 Cabazitaxel adverse events are manageable in senior adults with metastatic castration-resistant prostate<br />

cancer (mCRPC): Results of the European Compassionate Use <strong>Programme</strong><br />

A. Heidenreich, S. Bracarda, M. Mason, H. Ozen, L. Sengelov, W. Gerritsen, C. Papandreou, S. Fossa,<br />

S. Hitier, M. Climent (Aachen, Germany; Arezzo, Italy; Wales, United Kingdom; Ankara, Turkey; Herlev,<br />

Denmark; Nijmegen, The Netherlands; Larissa, Greece; Olso, Norway; Paris, France; Valencia, Spain)<br />

107 Evaluation of circulating tumor cells to predict metastatic progression in men treated with abirateron<br />

acetat for castration resistant prostate cancer: A sub-analysis of the German named patient program<br />

T. Steuber, P. Stroelin, T. Schlomm, H. Heinzer, K. Pantel, S. Riethdorf (Hamburg, Germany)<br />

108 Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time<br />

(PSADT) ≤6 months<br />

K. Miller, M.R. Smith, D. Dearnaley, L. Dogliotti, B. Egerdie, K. Fizazi, F. Kueppers, L. Montes De Oca,<br />

J. Morote, I. Pavlik, P. Sieber, T.L. Tammela, H. Van Poppel, M. Wirth, S. Wong, Z. Ye, A. Braun (Berlin,<br />

Dresden, Germany; Boston, Lancaster, Thousand Oaks, United States of America; Sutton, United Kingdom;<br />

Orbassano, Italy; Kitchener, Canada; Villejuif, France; Christchurch, New Zealand; Buenos Aires, Argentina;<br />

Barcelona, Spain; Prague, Czech Republic; Tampere, Finland; Leuven, Belgium; Footscray, Australia)<br />

<strong>EAU</strong> Milan <strong>2013</strong><br />

115<br />

Saturday

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!